Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allogene Therapeutics Inc ALLO

Healthcare Biotechnology
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a... see more

Recent & Breaking News (NDAQ:ALLO)

Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

GlobeNewswire April 12, 2021

Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR(TM) T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting

GlobeNewswire April 10, 2021

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

GlobeNewswire February 25, 2021

Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

GlobeNewswire February 18, 2021

Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences

GlobeNewswire February 9, 2021

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine

GlobeNewswire January 26, 2021

Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2021

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma

GlobeNewswire December 23, 2020

Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T(TM) Cell Therapies

GlobeNewswire December 15, 2020

Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR(TM) T Cell Therapy, at the 62nd Meeting of the American Society of Hematology

GlobeNewswire December 7, 2020

Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology

GlobeNewswire December 6, 2020

Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T(TM) Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting

GlobeNewswire December 5, 2020

Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020

GlobeNewswire December 2, 2020

Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference Participation

GlobeNewswire November 12, 2020

Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology

GlobeNewswire November 4, 2020

Allogene Therapeutics Reports Third Quarter 2020 Financial Results

GlobeNewswire November 4, 2020

Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020

GlobeNewswire October 27, 2020

Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T(TM))

GlobeNewswire October 15, 2020

Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation

GlobeNewswire October 1, 2020

Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation

GlobeNewswire September 2, 2020